

# ICM6011: Brain and Mind, Disorders of Supraspinal Systems

View Online



1

Blogger: Blogger Dashboard. <http://www.blogger.com/home?pli=1>

2

Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals.

[http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=3&ctx\\_ver=Z39.88-2004&ctx\\_enc=info:ofi/enc:UTF-8&ctx\\_tim=2013-07-10T05%3A25%3A53IST&url\\_ver=Z39.88-2004&url\\_ctx\\_fmt=info:ofi/fmt:kev:mtx:ctx&rft\\_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medline&rft\\_val\\_fmt=info:ofi/fmt:kev:mtx:article&rft.genre=article&rft.atitle=Enzymatic%20machinery%20for%20endocannabinoid%20biosynthesis%20associated%20with%20calcium%20stores%20in%20glutamatergic%20axon%20terminals.&rft.jtitle=The%20Journal%20of%20neuroscience%20:%20the%20official%20journal%20of%20the%20Society%20for%20Neuroscience&rft.btitle=&rft.aulast=Nyilas&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Nyilas%20Rita&rft.aucorp=&rft.date=20080130&rft.volume=28&rft.issue=5&rft.part=&rft.quarter=&rft.ssn=&rft.spage=1058&rft.epage=&rft.pages=1058-63&rft.artnum=&rft.issn=&rft.eissn=1529-2401&rft.isbn=&rft.sici=&rft.coden=&rft\\_id=info:doi/10.1523/JNEUROSCI.5102-07.2008&rft.object\\_id=&svc\\_val\\_fmt=info:ofi/fmt:kev:mtx:sch\\_svc&rft.eisbn=&rft\\_dat=%3Cmedline%3E18234884%3C/medline%3E&rft\\_id=info:oai/&svc.fulltext=yes](http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=3&ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2013-07-10T05%3A25%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&rft_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medline&rft_val_fmt=info:ofi/fmt:kev:mtx:article&rft.genre=article&rft.atitle=Enzymatic%20machinery%20for%20endocannabinoid%20biosynthesis%20associated%20with%20calcium%20stores%20in%20glutamatergic%20axon%20terminals.&rft.jtitle=The%20Journal%20of%20neuroscience%20:%20the%20official%20journal%20of%20the%20Society%20for%20Neuroscience&rft.btitle=&rft.aulast=Nyilas&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Nyilas%20Rita&rft.aucorp=&rft.date=20080130&rft.volume=28&rft.issue=5&rft.part=&rft.quarter=&rft.ssn=&rft.spage=1058&rft.epage=&rft.pages=1058-63&rft.artnum=&rft.issn=&rft.eissn=1529-2401&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/10.1523/JNEUROSCI.5102-07.2008&rft.object_id=&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&rft.eisbn=&rft_dat=%3Cmedline%3E18234884%3C/medline%3E&rft_id=info:oai/&svc.fulltext=yes)

3

The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus.

[http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=5&ctx\\_ver=Z39.88-2004&ctx\\_enc=info:ofi/enc:UTF-8&ctx\\_tim=2013-07-10T05%3A25%3A10IST&url\\_ver=Z39.88-2004&url\\_ctx\\_fmt=info:ofi/fmt:kev:mtx:ctx&rft\\_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sciversesciencedirect\\_elsevier&rft\\_val\\_fmt=info:ofi/fmt:kev:mtx:&rft.genre=article&rft.atitle=The%20Endocannabinoid%20System%20Controls%20Key%20Epileptogenic%20Circuits%20in%20the%20Hippocampus&rft.jtitle=Neuron&rft.btitle=&rft.aulast=Monory&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Monory%20Krisztina&rft.aucorp=&rft.date=2006&rft.volume=51&rft.issue=4&rft.part=&rft.quarter=&rft.ssn=&rft.spage=455&rft.epage=](http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=5&ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2013-07-10T05%3A25%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&rft_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sciversesciencedirect_elsevier&rft_val_fmt=info:ofi/fmt:kev:mtx:&rft.genre=article&rft.atitle=The%20Endocannabinoid%20System%20Controls%20Key%20Epileptogenic%20Circuits%20in%20the%20Hippocampus&rft.jtitle=Neuron&rft.btitle=&rft.aulast=Monory&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Monory%20Krisztina&rft.aucorp=&rft.date=2006&rft.volume=51&rft.issue=4&rft.part=&rft.quarter=&rft.ssn=&rft.spage=455&rft.epage=)

466&rft.pages=455-466&rft.artnum=&rft.issn=0896-6273&rft.eissn=&rft.isbn=&rft.sici=&rft.coden=&rft\_id=info:doi/10.1016/j.neuron.2006.07.006&rft.object\_id=&svc\_val\_fmt=info:ofi/fmt:kev:mtx:sch\_svc&rft.eisbn=&rft\_dat=%3Csciversesciencedirect\_elsevier%3ES0896-6273(06)00546-0%3C/sciversesciencedirect\_elsevier%3E&rft\_id=info:oai/&svc.fulltext=yes

4

Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures.

[http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=3&ctx\\_ver=Z39.88-2004&ctx\\_enc=info:ofi/enc:UTF-8&ctx\\_tim=2013-07-10T05%3A24%3A07IST&url\\_ver=Z39.88-2004&url\\_ctx\\_fmt=info:ofi/fmt:kev:mtx:ctx&rft\\_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medline&rft\\_val\\_fmt=info:ofi/fmt:kev:mtx:article&rft.genre=article&rft.atitle=Prevention%20of%20plasticity%20of%20endocannabinoid%20signaling%20inhibits%20persistent%20limbic%20hyperexcitability%20caused%20by%20developmental%20seizures.&rft.jtitle=The%20Journal%20of%20neuroscience%20:%20the%20official%20journal%20of%20the%20Society%20for%20Neuroscience&rft.btitle=&rft.aulast=Chen&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Chen%2C%20Kang&rft.aucorp=&rft.date=20070103&rft.volume=27&rft.issue=1&rft.part=&rft.quarter=&rft.ssn=&rft.spage=46&rft.epage=&rft.pages=46-58&rft.artnum=&rft.issn=&rft.eissn=1529-2401&rft.isbn=&rft.sici=&rft.coden=&rft\\_id=info:doi/&rft.object\\_id=&svc\\_val\\_fmt=info:ofi/fmt:kev:mtx:sch\\_svc&rft.eisbn=&rft\\_dat=%3Cmedline%3E17202471%3C/medline%3E&rft\\_id=info:oai/&svc.fulltext=yes](http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=3&ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2013-07-10T05%3A24%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&rft_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medline&rft_val_fmt=info:ofi/fmt:kev:mtx:article&rft.genre=article&rft.atitle=Prevention%20of%20plasticity%20of%20endocannabinoid%20signaling%20inhibits%20persistent%20limbic%20hyperexcitability%20caused%20by%20developmental%20seizures.&rft.jtitle=The%20Journal%20of%20neuroscience%20:%20the%20official%20journal%20of%20the%20Society%20for%20Neuroscience&rft.btitle=&rft.aulast=Chen&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Chen%2C%20Kang&rft.aucorp=&rft.date=20070103&rft.volume=27&rft.issue=1&rft.part=&rft.quarter=&rft.ssn=&rft.spage=46&rft.epage=&rft.pages=46-58&rft.artnum=&rft.issn=&rft.eissn=1529-2401&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/&rft.object_id=&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&rft.eisbn=&rft_dat=%3Cmedline%3E17202471%3C/medline%3E&rft_id=info:oai/&svc.fulltext=yes)

5

The synaptic vesicle cycle: a cascade of protein-protein interactions.

<http://www.nature.com.ezproxy.library.qmul.ac.uk/nature/journal/v375/n6533/pdf/375645a0.pdf>

6

Synaptic transmission: a bi-directional and self-modifiable form of cell-cell communication.

[http://ac.els-cdn.com/S009286740580025X/1-s2.0-S009286740580025X-main.pdf?\\_tid=009b8a8e-3c51-11e4-b122-00000aacb360&acdnat=1410728112\\_021201c27a3e63f656189186490abaa6](http://ac.els-cdn.com/S009286740580025X/1-s2.0-S009286740580025X-main.pdf?_tid=009b8a8e-3c51-11e4-b122-00000aacb360&acdnat=1410728112_021201c27a3e63f656189186490abaa6)

7

Presynaptic receptors.

<http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/pdf/10.1146/annurev.pharmtox.38.1.201>

8

25 years since the discovery of presynaptic receptors: present knowledge and future perspectives.

[http://ac.els-cdn.com/S0165614796010346/1-s2.0-S0165614796010346-main.pdf?\\_tid=a20c5992-3c52-11e4-affe-00000aab0f26&acdnat=1410728813\\_db0468ec082f8cff0ef65cdbaba300ef](http://ac.els-cdn.com/S0165614796010346/1-s2.0-S0165614796010346-main.pdf?_tid=a20c5992-3c52-11e4-affe-00000aab0f26&acdnat=1410728813_db0468ec082f8cff0ef65cdbaba300ef)

9

Presynaptic inhibition of elicited neurotransmitter release.

[http://ac.els-cdn.com/S0166223696010156/1-s2.0-S0166223696010156-main.pdf?\\_tid=f1e9cc4c-3c52-11e4-9b26-00000aacb35f&acdnat=1410728947\\_43699bcaa58c68c76829e15a92277b73](http://ac.els-cdn.com/S0166223696010156/1-s2.0-S0166223696010156-main.pdf?_tid=f1e9cc4c-3c52-11e4-9b26-00000aacb35f&acdnat=1410728947_43699bcaa58c68c76829e15a92277b73)

10

Presynaptic inhibition of elicited neurotransmitter release.

[http://ac.els-cdn.com/S0166223696010156/1-s2.0-S0166223696010156-main.pdf?\\_tid=f1e9cc4c-3c52-11e4-9b26-00000aacb35f&acdnat=1410728947\\_43699bcaa58c68c76829e15a92277b73](http://ac.els-cdn.com/S0166223696010156/1-s2.0-S0166223696010156-main.pdf?_tid=f1e9cc4c-3c52-11e4-9b26-00000aacb35f&acdnat=1410728947_43699bcaa58c68c76829e15a92277b73)

11

Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures.

<http://www.jneurosci.org.ezproxy.library.qmul.ac.uk/content/27/1/46.full.pdf+html>

12

The endocannabinoid system controls key epileptogenic circuits in the hippocampus.

[http://ac.els-cdn.com/S0896627306005460/1-s2.0-S0896627306005460-main.pdf?\\_tid=6cce1e9e-3c54-11e4-b6b0-00000aacb360&acdnat=1410729582\\_711cb09225d5ffd6729eb8217664c51b](http://ac.els-cdn.com/S0896627306005460/1-s2.0-S0896627306005460-main.pdf?_tid=6cce1e9e-3c54-11e4-b6b0-00000aacb360&acdnat=1410729582_711cb09225d5ffd6729eb8217664c51b)

13

Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals.

<http://www.jneurosci.org.ezproxy.library.qmul.ac.uk/content/28/5/1058.full.pdf+html>

14

Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. *British Journal of Pharmacology* 2009;**154**:369–83. doi:10.1038/bjp.2008.130

15

Signalling via CNS cannabinoid receptors.

[http://ac.els-cdn.com/S0303720708000324/1-s2.0-S0303720708000324-main.pdf?\\_tid=2f1eb264-3c56-11e4-8497-00000aab0f6c&acdnat=1410730338\\_15b6a5eba718f297e2ad659d423af29f](http://ac.els-cdn.com/S0303720708000324/1-s2.0-S0303720708000324-main.pdf?_tid=2f1eb264-3c56-11e4-8497-00000aab0f6c&acdnat=1410730338_15b6a5eba718f297e2ad659d423af29f)

16

Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

[http://ac.els-cdn.com/S0306452200005169/1-s2.0-S0306452200005169-main.pdf?\\_tid=7d42c534-3c56-11e4-8ec2-00000aacb35e&acdnat=1410730469\\_0edbb97e316622b92c8b7b80361ff857](http://ac.els-cdn.com/S0306452200005169/1-s2.0-S0306452200005169-main.pdf?_tid=7d42c534-3c56-11e4-8ec2-00000aacb35e&acdnat=1410730469_0edbb97e316622b92c8b7b80361ff857)

17

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease.

[http://ac.els-cdn.com/S0165614702020382/1-s2.0-S0165614702020382-main.pdf?\\_tid=c7580bd4-3c56-11e4-9515-00000aacb35e&acdnat=1410730593\\_5f80331cd9335e75babf21ea791761e4](http://ac.els-cdn.com/S0165614702020382/1-s2.0-S0165614702020382-main.pdf?_tid=c7580bd4-3c56-11e4-9515-00000aacb35e&acdnat=1410730593_5f80331cd9335e75babf21ea791761e4)

18

Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?

[http://ac.els-cdn.com/S0006322399001651/1-s2.0-S0006322399001651-main.pdf?\\_tid=16940986-3c56-11e4-8d5e-00000aab0f27&acdnat=1410731156\\_ea2ac6412e32b4b78b2fed3496951005](http://ac.els-cdn.com/S0006322399001651/1-s2.0-S0006322399001651-main.pdf?_tid=16940986-3c56-11e4-8d5e-00000aab0f27&acdnat=1410731156_ea2ac6412e32b4b78b2fed3496951005)

19

Which GABAA-receptor subtypes really occur in the brain?

[http://ac.els-cdn.com/S0166223696800233/1-s2.0-S0166223696800233-main.pdf?\\_tid=75ec1f36-3c58-11e4-85ec-00000aab0f01&acdnt=1410731316\\_dc1140684ef448767c917608f7ef95e5](http://ac.els-cdn.com/S0166223696800233/1-s2.0-S0166223696800233-main.pdf?_tid=75ec1f36-3c58-11e4-85ec-00000aab0f01&acdnt=1410731316_dc1140684ef448767c917608f7ef95e5)

20

NMDA receptors: from genes to channels.

[http://ac.els-cdn.com/S0165614796800083/1-s2.0-S0165614796800083-main.pdf?\\_tid=c1d1c446-3c58-11e4-9397-00000aacb361&acdnt=1410731443\\_081c590ff059c4eb7bafa6c1f419bef9](http://ac.els-cdn.com/S0165614796800083/1-s2.0-S0165614796800083-main.pdf?_tid=c1d1c446-3c58-11e4-9397-00000aacb361&acdnt=1410731443_081c590ff059c4eb7bafa6c1f419bef9)

21

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.

[http://www.nature.com/nrn/journal/v2/n8/pdf/nrn0801\\_577a.pdf](http://www.nature.com/nrn/journal/v2/n8/pdf/nrn0801_577a.pdf)

22

Huntington's disease: new hope for therapeutics.

[http://ac.els-cdn.com/S0166223600019974/1-s2.0-S0166223600019974-main.pdf?\\_tid=606a2c26-3c5c-11e4-a01e-00000aab0f02&acdnt=1410732998\\_957fcf339fa1c1626d376a540af8b437](http://ac.els-cdn.com/S0166223600019974/1-s2.0-S0166223600019974-main.pdf?_tid=606a2c26-3c5c-11e4-a01e-00000aab0f02&acdnt=1410732998_957fcf339fa1c1626d376a540af8b437)

23

The benzodiazepine binding site of GABAA receptors.

[http://ac.els-cdn.com/S0165614797011188/1-s2.0-S0165614797011188-main.pdf?\\_tid=fb d40038-3c5c-11e4-a7b6-00000aacb362&acdnt=1410733258\\_871d841b33321546e4fb56e2df89c890](http://ac.els-cdn.com/S0165614797011188/1-s2.0-S0165614797011188-main.pdf?_tid=fb d40038-3c5c-11e4-a7b6-00000aacb362&acdnt=1410733258_871d841b33321546e4fb56e2df89c890)

24

Benzodiazepines on trial: a research strategy for their rehabilitation.

[http://ac.els-cdn.com/0165614796100158/1-s2.0-0165614796100158-main.pdf?\\_tid=4055e99c-3c5d-11e4-b472-00000aacb360&acdnt=1410733373\\_adf79f6a94b011e6f6c582c2db5ce13d](http://ac.els-cdn.com/0165614796100158/1-s2.0-0165614796100158-main.pdf?_tid=4055e99c-3c5d-11e4-b472-00000aacb360&acdnt=1410733373_adf79f6a94b011e6f6c582c2db5ce13d)

25

Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?

[http://ac.els-cdn.com/S0166223699014630/1-s2.0-S0166223699014630-main.pdf?\\_tid=76ab6710-3c5d-11e4-8b2e-00000aab0f27&acdnat=1410733464\\_1f833265d8ae90ebc3425fb58f3cac0e](http://ac.els-cdn.com/S0166223699014630/1-s2.0-S0166223699014630-main.pdf?_tid=76ab6710-3c5d-11e4-8b2e-00000aab0f27&acdnat=1410733464_1f833265d8ae90ebc3425fb58f3cac0e)

26

Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels - 1-s2.0-S0306452208014024-main.pdf.

[http://ac.els-cdn.com/S0306452208014024/1-s2.0-S0306452208014024-main.pdf?\\_tid=b4cf5a24-3c5d-11e4-bfa0-00000aab0f26&acdnat=1410733569\\_6b926f4090406133b19dd49c4a2f5015](http://ac.els-cdn.com/S0306452208014024/1-s2.0-S0306452208014024-main.pdf?_tid=b4cf5a24-3c5d-11e4-bfa0-00000aab0f26&acdnat=1410733569_6b926f4090406133b19dd49c4a2f5015)

27

Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. <http://www.nature.com/nm/journal/v7/n9/pdf/nm0901-1003.pdf>

28

Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.

[http://www.nature.com.ezproxy.library.qmul.ac.uk/ng/journal/v24/n4/pdf/ng0400\\_410.pdf](http://www.nature.com.ezproxy.library.qmul.ac.uk/ng/journal/v24/n4/pdf/ng0400_410.pdf)

29

Schizophrenia: New Pathological Insights and Therapies - *annurev.med.58.060904.084114*. <http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/pdf/10.1146/annurev.med.58.060904.084114>

30

Iritani S. Neuropathology of schizophrenia: A mini review. *Neuropathology* 2007;**27**:604–8. doi:10.1111/j.1440-1789.2007.00798.x

31

LARUELLE M, KEGELES LS, ABI-DARGHAM A. Glutamate, Dopamine, and Schizophrenia. *Annals of the New York Academy of Sciences* 2003;**1003**:138–58.  
doi:10.1196/annals.1300.063

32

LARUELLE M, KEGELES LS, ABI-DARGHAM A. Glutamate, Dopamine, and Schizophrenia. *Annals of the New York Academy of Sciences* 2003;**1003**:138–58.  
doi:10.1196/annals.1300.063

33

Neurochemical markers for schizophrenia, bipolar disorder, and major depression in post-mortem brains.  
[http://ac.els-cdn.com/S0006322304010996/1-s2.0-S0006322304010996-main.pdf?\\_tid=7fbcd48c-3c63-11e4-a35f-00000aab0f01&acdnat=1410736057\\_d16efce424c97c998802cda d24ad4012](http://ac.els-cdn.com/S0006322304010996/1-s2.0-S0006322304010996-main.pdf?_tid=7fbcd48c-3c63-11e4-a35f-00000aab0f01&acdnat=1410736057_d16efce424c97c998802cda d24ad4012)

34

Current status and future directions in the pharmacotherapy of epilepsy.  
[http://ac.els-cdn.com/S016561470001974X/1-s2.0-S016561470001974X-main.pdf?\\_tid=c2e5d5ec-3c63-11e4-b570-00000aacb360&acdnat=1410736169\\_9bee4023b6baabd182302 eb55b065abf](http://ac.els-cdn.com/S016561470001974X/1-s2.0-S016561470001974X-main.pdf?_tid=c2e5d5ec-3c63-11e4-b570-00000aacb360&acdnat=1410736169_9bee4023b6baabd182302 eb55b065abf)

35

Channelopathies as a genetic cause of epilepsy,.  
[http://ovidsp.tx.ovid.com.ezproxy.library.qmul.ac.uk/sp-3.13.0b/ovidweb.cgi?WebLinkFrameSet=1&S=HHIPFPPNMFDDJOCJNCLKKHJCCKJAA00&returnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c00019052-200304000-00009%26S%3dHHIPFPPNMFDDJOCJNCLKKHJCCKJAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCJCKHCJMF00%2ffs004%2fovft%2flive%2fgv006%2f00019052%2f00019052-200304000-00009.pdf&filename=Channelopathies+as+a+genetic+cause+of+epilepsy.&pdf\\_key=FPDDNCJCKHCJMF00&pdf\\_index=/fs004/ovft/live/gv006/00019052/00019052-200304000-00009](http://ovidsp.tx.ovid.com.ezproxy.library.qmul.ac.uk/sp-3.13.0b/ovidweb.cgi?WebLinkFrameSet=1&S=HHIPFPPNMFDDJOCJNCLKKHJCCKJAA00&returnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c00019052-200304000-00009%26S%3dHHIPFPPNMFDDJOCJNCLKKHJCCKJAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCJCKHCJMF00%2ffs004%2fovft%2flive%2fgv006%2f00019052%2f00019052-200304000-00009.pdf&filename=Channelopathies+as+a+genetic+cause+of+epilepsy.&pdf_key=FPDDNCJCKHCJMF00&pdf_index=/fs004/ovft/live/gv006/00019052/00019052-200304000-00009)

36

The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies - 1-s2.0-S0165017308001045-main.pdf.

[http://ac.els-cdn.com/S0165017308001045/1-s2.0-S0165017308001045-main.pdf?\\_tid=6c088be2-3c64-11e4-8862-00000aacb35f&acdnat=1410736453\\_53d6ee0580d148eb6b63b36063740a15](http://ac.els-cdn.com/S0165017308001045/1-s2.0-S0165017308001045-main.pdf?_tid=6c088be2-3c64-11e4-8862-00000aacb35f&acdnat=1410736453_53d6ee0580d148eb6b63b36063740a15)

37

Schmitz B, Montouris G, Schäuble B, et al. Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control. *Epilepsia* 2010;**51**:2231-40. doi:10.1111/j.1528-1167.2010.02759.x

38

Volkow, N.D., Fowler, J.S., Wang, G.J. (2004) The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. *Neuropharmacology*, 47: 3-13. [http://ac.els-cdn.com/S0028390804002163/1-s2.0-S0028390804002163-main.pdf?\\_tid=d8687f4a-3c64-11e4-8ec3-00000aacb35e&acdnat=1410736635\\_bdf7036b1652a7f1a078294b2e6b5a2e](http://ac.els-cdn.com/S0028390804002163/1-s2.0-S0028390804002163-main.pdf?_tid=d8687f4a-3c64-11e4-8ec3-00000aacb35e&acdnat=1410736635_bdf7036b1652a7f1a078294b2e6b5a2e)

39

Is there a common molecular pathway for addiction?  
<http://www.nature.com/neuro/journal/v8/n11/pdf/nn1578.pdf>

40

Neurobiology of addiction: treatment and public policy ramifications.  
<http://www.nature.com/neuro/journal/v8/n11/pdf/nn1105-1431.pdf>